Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) is ripping 36 percent in pre-open trading Tuesday following "tentative" FDA approval for Trokendi XR.
This article: 108 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE